These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 15459425

  • 1. Bisphosphonates: preclinical review.
    Green JR.
    Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW.
    J Urol; 2003 Jul 01; 170(1):246-52. PubMed ID: 12796698
    [Abstract] [Full Text] [Related]

  • 7. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH.
    Ann N Y Acad Sci; 2007 Nov 01; 1117():209-57. PubMed ID: 18056045
    [Abstract] [Full Text] [Related]

  • 8. Potential anticancer properties of bisphosphonates.
    Neville-Webbe HL, Gnant M, Coleman RE.
    Semin Oncol; 2010 Jun 01; 37 Suppl 1():S53-65. PubMed ID: 20682373
    [Abstract] [Full Text] [Related]

  • 9. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
    Mitrofan LM, Pelkonen J, Mönkkönen J.
    Bone; 2009 Dec 01; 45(6):1153-60. PubMed ID: 19699819
    [Abstract] [Full Text] [Related]

  • 10. Toward new horizons: the future of bisphosphonate therapy.
    Lipton A.
    Oncologist; 2004 Dec 01; 9 Suppl 4():38-47. PubMed ID: 15459428
    [Abstract] [Full Text] [Related]

  • 11. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [Abstract] [Full Text] [Related]

  • 12. New role for an established drug? Bisphosphonates as potential anticancer agents.
    Koul HK, Koul S, Meacham RB.
    Prostate Cancer Prostatic Dis; 2012 Jun 15; 15(2):111-9. PubMed ID: 21876554
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonates for the prevention of bone metastases.
    Coleman RE.
    Semin Oncol; 2002 Dec 15; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [Abstract] [Full Text] [Related]

  • 14. The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Green JR, Guenther A.
    Crit Rev Oncol Hematol; 2011 Feb 15; 77 Suppl 1():S3-S12. PubMed ID: 21353178
    [Abstract] [Full Text] [Related]

  • 15. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb 15; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 16. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S, Kamiya S, Ono K.
    Clin Calcium; 2005 May 15; 15(5):819-24. PubMed ID: 15876745
    [Abstract] [Full Text] [Related]

  • 17. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
    Clézardin P.
    Bone; 2011 Jan 15; 48(1):71-9. PubMed ID: 20655399
    [Abstract] [Full Text] [Related]

  • 18. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA, Rodan GA.
    Mini Rev Med Chem; 2004 Sep 15; 4(7):711-9. PubMed ID: 15379639
    [Abstract] [Full Text] [Related]

  • 19. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug 15; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis.
    Green JR, Clézardin P.
    Am J Clin Oncol; 2002 Dec 15; 25(6 Suppl 1):S3-9. PubMed ID: 12562045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.